This page shows the latest bladder cancer news and features for those working in and with pharma, biotech and healthcare.
chemotherapy alone as a first-line treatment for advanced biliary tract cancer (BTC). ... Imfinzi has been used to treat patients with non-small cell lung cancer since 2017, and is also indicated for use in advanced bladder cancer in several countries.
Imfinzi is already used to treat unresectable, stage 3 non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC) as well as advanced bladder cancer. ... The company has a broad development programme for Imfinzi plus
It is also widely approved in non-small cell lung cancer (NSCLC) in unresectable, stage 3 disease after CRT and in previously treated patients with advanced bladder cancer. ... As part of a broad development programme, Imfinzi is being tested as a single
TNBC patients generally experience rapid progression and shorter overall survival compared to other subtypes of breast cancer. ... Other immuno-oncology drugs with accelerated approval have also been withdrawn this year: BMS withdrew Opdivo in liver
cancer indications as well as uptake in other indications such as adjuvant melanoma, bladder cancer and MSI-H cancers.
We are grateful to the FDA and ODAC for the open dialogue and look forward to continued collaboration to improve the lives of people with breast cancer,” he added. ... The ODAC is set to reconvene today to discuss the accelerated approval for Tecentriq
More from news
Approximately 29 fully matching, plus 123 partially matching documents found.
those living with urothelial carcinoma (UC), the most common type of bladder cancer. ... and metastatic bladder cancer harbouring an FGFR alteration, addressing the considerable unmet need for patients living with this disease.
This treatment quickly became the ‘gold standard’ for women with metastatic breast cancer. ... a terminal disease, and more towards helping cancer patients manage their condition effectively.
had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Cavatak is now in three trials in melanoma, bladder cancer and NSCLC that are due to generate results in 2018/2019.
Immunomic Therapeutics will retain the rights to its LAMP-vax platform for other applications, including cancer immunotherapy. ... MCNA for non-muscle invasive bladder cancer (BLA filed). Licence. 137. Proteros biostructures/ Merck &Co.
There's prostate cancer drug orteronel (TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... drug and the risk of bladder cancer.
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
It’s the first major appointment for Ferring in 2019, and the company says Opdyke will lead the potential commercial launch of its investigational gene therapy for bladder cancer patients in ... He said: “At the heart of cancer immunity is a T cell
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
The objective for this congress is for HCPs to learn from physicians and scientists who present their research in prostate, bladder, and kidney cancer. ... highlighting the ground-breaking research in cancer care.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...